Status:
RECRUITING
Arterial Embolism After Catheter Ablation of Atrial Fibrillation. ATRIAL FIBRILLATION
Lead Sponsor:
Hospital Universitario La Paz
Collaborating Sponsors:
3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.
Department of Rhythmology, University Hospital Schleswig-Holstein, Lübeck, Germany.
Conditions:
Arrhythmia
Atrial Fibrillation
Eligibility:
All Genders
Brief Summary
The EMBOL-AF is a multicenter, international, observational study designed as a retrospective registry that will investigate the characteristics of systemic arterial embolic events after treatment of ...
Detailed Description
BACKGROUND Arterial embolisms, particularly brain embolism (stroke or TIA) is one of the most clinically relevant complications of AFAbl procedures. According to the 2017 HRS/EHRA/ECAS/APHRS/SOLAECE ...
Eligibility Criteria
Inclusion
- Systemic arterial embolism (stroke, TIA or any other symptomatic event) after catheter ablation for AF or left atrial macroreentrant atrial tachycardia or left atrial flutter that have occurred between 1st january 2017 and 31st july 2023.
- The embolic event must be associated with the ablation procedure, therefore, it must have occurred during the procedure or during the first 7 days after it, during hospital stay or after discharge.
Exclusion
- The embolic event that occurred during the first 7 days after the ablation procedure can be undoubtedly attributed to other causes, such as surgery (cardiac, aortic or carotidal) or percutaneous interventions (coronary, cardiac structural, aortic or carotidal).
Key Trial Info
Start Date :
January 2 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06134739
Start Date
January 2 2024
End Date
December 1 2024
Last Update
January 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Departmen of Cardiology, La Paz University Hospital
Madrid, Spain